Apathy After Stroke.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
13 Feb 2024
Historique:
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: ppublish

Résumé

Apathy is one of the most common symptoms following stroke and is often associated with worse functional outcome and poor quality of life (QoL). The trajectory of apathy symptoms has been previously described, and different trajectories have been identified. We determined group and individual changes in apathy symptomatology from the acute phase until 1 year after stroke. We also examined the association of apathy and depression with disability and QoL 1 year after stroke. We measured apathy in a cohort of ischemic stroke survivors at 4 time points from 0 to 12 months after stroke. The Apathy Evaluation Scale (AES) and Dimensional Apathy Scale (DAS) were administered at each time point. Where possible we obtained apathy measured from carers. Depression was assessed with the Geriatric Depression Scale (GDS). Disability and QoL were assessed with the modified Rankin Scale (mRS) and 36-Item Short Form Survey (SF-36). We examined the cross-sectional and individual trajectory of apathy symptoms in each dimension and looked at associations of apathy and depression soon after stroke with mRS and SF-36 at 1 year. Of 200 participants enrolled, 165 completed apathy measures at 12 months. Patient-rated apathy scores increased in both tests at the group level (AES: χ Self-reported apathy progressively increases after stroke, especially in the executive dimension. Apathy is associated with worse QoL and greater disability, although some of these associations might be mediated by depression.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Apathy is one of the most common symptoms following stroke and is often associated with worse functional outcome and poor quality of life (QoL). The trajectory of apathy symptoms has been previously described, and different trajectories have been identified. We determined group and individual changes in apathy symptomatology from the acute phase until 1 year after stroke. We also examined the association of apathy and depression with disability and QoL 1 year after stroke.
METHODS METHODS
We measured apathy in a cohort of ischemic stroke survivors at 4 time points from 0 to 12 months after stroke. The Apathy Evaluation Scale (AES) and Dimensional Apathy Scale (DAS) were administered at each time point. Where possible we obtained apathy measured from carers. Depression was assessed with the Geriatric Depression Scale (GDS). Disability and QoL were assessed with the modified Rankin Scale (mRS) and 36-Item Short Form Survey (SF-36). We examined the cross-sectional and individual trajectory of apathy symptoms in each dimension and looked at associations of apathy and depression soon after stroke with mRS and SF-36 at 1 year.
RESULTS RESULTS
Of 200 participants enrolled, 165 completed apathy measures at 12 months. Patient-rated apathy scores increased in both tests at the group level (AES: χ
DISCUSSION CONCLUSIONS
Self-reported apathy progressively increases after stroke, especially in the executive dimension. Apathy is associated with worse QoL and greater disability, although some of these associations might be mediated by depression.

Identifiants

pubmed: 38207223
doi: 10.1212/WNL.0000000000208052
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e208052

Auteurs

Claudia Pallucca (C)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Danuta M Lisiecka-Ford (DM)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Lisa Wood (L)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Azim Abul (A)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Amy A Jolly (AA)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Daniel J Tozer (DJ)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Steven Bell (S)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Anne Forster (A)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Robin G Morris (RG)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Hugh S Markus (HS)

From the Department of Clinical Neurosciences (C.P., D.M.L.-F., A.A.J., D.J.T., S.B., H.S.M.), University of Cambridge; Stroke Unit (L.W., A.A.), West Suffolk NHS Foundation Trust; Academic Unit for Aging and Stroke Research (A.F.), University of Leeds; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Classifications MeSH